Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | HTR2C | P28335 | 1/20 | 0.98 |
| ▸ | HRH1 | P35367 | 1/20 | 0.98 |
| ▸ | HTR2B | P41595 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700496 | 1.00 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL29754193 | 1.00 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL119933 | 1.00 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL29870266 | 1.00 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL8733354 | 1.00 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL8731569 | 0.99 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL29407476 | 0.99 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL8731566 | 0.99 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL4913461 | 0.99 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4912732 | 0.97 | TACR1 (0.94) | TACR1CYP2D6KCNH2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419861-B2 | Method for preventing and/or treating chronic traumatic encephalopathy-i | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2025-09-23 | — | — | US | claimed |
| US-11426384-B2 | Method for preventing and/or treating chronic traumatic encephalopathy-i | EUSTRALIS PHARMACEUTICALS LIMITED (Trading as Pressure Neuro) (AU) | 2022-08-30 | — | — | US | claimed |
| JP-7110850-B2 | — | マツダ株式会社 | 2022-08-02 | — | — | JP | claimed |
| US-20220218663-A1 | METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2022-07-14 | — | — | US | claimed |
| US-20080132538-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | PFIZER INC | 2008-06-05 | — | — | US | claimed |
| US-20050256162-A1 | Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| EP-1027892-B1 | Azithromycin combination for emesis control in dogs | PFIZER PROD INC (US) | 2005-08-17 | — | — | EP | claimed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| US-20040167200-A1 | Pharmaceutical composition and method of modulating cholinergic function in a mammal | PFIZER INC. | 2004-08-26 | — | — | US | claimed |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | BOYCE SUSAN (GB) | 2004-05-20 | — | — | US | claimed |
| US-5393762-A | Pharmaceutical agents for treatment of emesis | PFIZER INC. (US) | 1995-02-28 | — | — | US | claimed |
| WO-1994027966-A1 | PROCESS FOR PREPARING AND RESOLVING 2-PHENYL-3-AMINOPIPERIDINE | PFIZER INC. (US) | 1994-12-08 | — | — | WO | claimed |
| EP-0627221-A2 | Substance P antagonists for the treatment of emesis | PFIZER INC. (US) | 1994-12-07 | — | — | EP | claimed |
| EP-0619806-A1 | PREPARATION OF SUBSTITUTED PIPERIDINES. | PFIZER (US) | 1994-10-19 | — | — | EP | claimed |
| EP-0615751-A1 | Use of tachykinin antagonists in the treatment of emesis | GLAXO GROUP LIMITED (GB) | 1994-09-21 | — | — | EP | claimed |
| US-5340826-A | Pharmaceutical agents for treatment of urinary incontinence | PFIZER INC. (US) | 1994-08-23 | — | — | US | claimed |
| EP-0610021-A1 | Pharmaceutical agents for treatment of urinary incontinence | PFIZER INC. (US) | 1994-08-10 | — | — | EP | claimed |
| EP-0589924-A1 | FLUOROALKOXYBENZYLAMINO DERIVATIVES OF NITROGEN CONTAINING HETEROCYCLES. | PFIZER (US) | 1994-04-06 | — | — | EP | claimed |
| WO-1993011110-A1 | PREPARATION OF SUBSTITUTED PIPERIDINES | PFIZER INC. (US) | 1993-06-10 | — | — | WO | claimed |
| WO-1993000331-A1 | FLUOROALKOXYBENZYLAMINO DERIVATIVES OF NITROGEN CONTAINING HETEROCYCLES | PFIZER INC. (US) | 1993-01-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132538-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | NMUR2, NMUR1, NMBR | TACR1 41/4885CYP2D6 723/4885KCNH2 331/4885 |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | PTGS1, PTGS2, PTGES2 | TACR1 34/4885CYP2D6 880/4885KCNH2 532/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | TACR1 190/4885CYP2D6 1379/4885KCNH2 992/4885 |
| US-20050256162-A1 | Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | FPR3, CX3CR1, FPR1 | TACR1 564/4885CYP2D6 319/4885KCNH2 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.